Latest Regulatory News

Fletcher Building has agreed to sell its Construction Division to global giant VINCI Construction for an initial $315.6 million, with potential to rise to $334.1 million. The move marks a strategic pivot towards focused building products manufacturing.

Identitii Limited has voluntarily suspended trading of its deferred settlement securities following a takeover dispute initiated by Mitchell Asset Management. The suspension awaits a critical announcement on the Takeovers Panel's decision.

Yancoal has reported record coal production and sales for 2025, achieving near the top of its guidance range with improved realised prices despite challenging market conditions. The company’s robust cash position and disciplined cost management position it well for future growth.

Richmond Vanadium Technology Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, confirming no undisclosed information is driving the activity and attributing the surge to broader market interest and improved liquidity.

AuKing Mining reports promising exploration results at Myoff Creek and steady progress at Koongie Park, while grappling with a failed Cloncurry acquisition and significant board changes.

The a2 Milk Company has responded to an ASX price query denying any undisclosed information behind recent share price moves, attributing the volatility to China’s latest birth statistics.

Phoslock Environmental Technologies has amended its December 2025 quarterly report to correct funding data and withdraw its sales outlook, while reporting improved cash flow and resuming factory operations.

Alice Queen Limited (AQX) has had its trading suspension lifted immediately following its response to an ASX Price Query, reopening access for investors.

Arena REIT has announced an ordinary quarterly dividend of AUD 0.048125 per security, payable on 5 February 2026, alongside a Dividend Reinvestment Plan priced at AUD 3.50330, offering investors a 1.5% discount.

DXN Limited has signed a strategic MOU with Super Sistem Indonesia to form a joint venture targeting Indonesia’s rapidly expanding digital infrastructure market, aiming for US$7 million in revenue over three years.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Nickel Industries faced a challenging December quarter due to delayed regulatory approvals impacting ore sales, yet the company kicked off 2026 with robust nickel ore sales and record earnings from its HPAL project.